첫 페이지 News 본문

The pre-market decline of Novo Nordisk's US stock market narrowed to 20%, after a sharp drop of nearly 30% at one point, marking the largest single day decline on record, as the trial results of Novo Nordisk's weight loss drug CagriSema fell short of expectations.
您需要登录后才可以回帖 登录 | Sign Up

本版积分规则

xinhui123 新手上路
  • Follow

    0

  • Following

    0

  • Articles

    0